The 5th Inflammasome Therapeutics Summit returns to unite industry pioneers at a critical time as clinical readouts are expected, and a wave of new collaborations hit the headlines.
As we focus on more inflammasomes beyond NLRP3, they are becoming prominent as potential targets for treating inflammation with drugs. This is a chance for you to join forces with like-minded individuals who prioritize inflammasome therapeutics.
Together, we can address important aspects such as discovery science and mechanisms, overcoming challenges related to biomarkers, selecting the right diseases to target, and making progress in developing preclinical models.
This is the largest gathering of inflammasome biopharma experts and pioneers set to advance inflammasome inhibitors and activators from the pipeline to in-human efficacy.
Gathering industry super giants, including NodThera, Novartis, Roche, Ventus, AC Immune, and more, this is your chance to join forces with 100+ inflammasome pioneers for interactive discussions.